Cumberland shares DMD and cancer trial data, closes Apotex sale in Q2 update

Cumberland Pharmaceuticals reported second quarter 2026 financial results on August 4, 2026, along with updates on its clinical pipeline following the close of its transaction with Apotex Health. During the quarter, Cumberland completed a deal with Apotex Health, described as the largest Canadian pharmaceutical company, under which Apotex acquired Cumberland's FDA-approved branded products and commercial operations for $100 million in cash at closing, with an additional $11 million allocated for inventory and transition support.¹

In June 2026, Cumberland presented updated data from its Phase 2 "FIGHT DMD" trial of ifetroban in Duchenne muscular dystrophy-associated cardiomyopathy at the Parent Project Muscular Dystrophy Conference. New blood biomarker data showed changes consistent with heart muscle protection, including increases in cardiac protection and repair markers and reductions in markers of heart injury, supporting earlier reported improvements in cardiac function.¹

Cumberland also reported results from a randomized, placebo-controlled Phase 2 study with Vanderbilt Health testing ifetroban to prevent cancer metastasis in patients with Stage I to III solid tumors at high risk of recurrence. The study met its primary safety and feasibility objective, with ifetroban found to be safe and well tolerated and no clotting-related safety signals.¹ As a secondary endpoint, metastatic recurrence occurred in 3 of 18 ifetroban patients (17%) versus 5 of 10 placebo patients (50%), a difference that was not statistically significant (odds ratio 0.21; p=0.09), while no ifetroban patients died from metastatic disease compared with 3 of 10 placebo patients (p=0.037).¹

On finances, the company posted a loss from continuing operations of $3.1 million and a net loss of $4.1 million for the quarter.¹ Total assets were about $63 million with $4 million in cash as of June 30, 2026, liabilities of $46 million, shareholders' equity of $17 million, and repayment of its $5.2 million bank line of credit.¹ The board declared a $1.50 per share special dividend, paid July 31, 2026 to shareholders of record as of July 23, 2026.¹